"Results of a secondary analysis of the CALYPSO trial indicated that patients who received carboplatin/pegylated liposomal doxorubicin reported higher quality of life indicators than patients who received carboplatin/paclitaxel.
The current paper reports on health-related quality of life (QOL) in patients from the CALYPSO trial, the results of which indicated that carboplatin/pegylated liposomal doxorubicin was linked to a superior therapeutic index compared with carboplatin/paclitaxel in patients with recurrent ovarian cancer..."